Wedbush Analysts Sees Halozyme (HALO) Stock at $17 Per Share
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $38.46 -1.69%
Rating Summary:
16 Buy, 5 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Rating Summary:
16 Buy, 5 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Join SI Premium – FREE
Wedbush reiterated an Outperform rating on Halozyme Therapeutics (NASDAQ: HALO) and raised its price target to $17.00 (from $13.00).
Halozyme Therapeutics remains in Wedbush’s BEST IDEA’S LIST, and analysts have a bullish view of the company's potential in the growing insulin pump market with the Hylenex delivery system.
"Hylenex for insulin pumps offers several advantages to the current standard of care, including faster onset and more physiologic response," said analyst Gregory R. Wade, Ph.D.
"Halozyme has made significant efforts towards commercialization of Hylenex for insulin pumps, we anticipate insight into timing to be the next significant catalyst for this opportunity," added Wade.
He thinks Halozyme may begin to derive revenues from the Hylenex insulin product in the fourth quarter of 2013.
For an analyst ratings summary and ratings history on Halozyme Therapeutics click here. For more ratings news on Halozyme Therapeutics click here.
Shares of Halozyme Therapeutics closed at $6.79 yesterday.
Halozyme Therapeutics remains in Wedbush’s BEST IDEA’S LIST, and analysts have a bullish view of the company's potential in the growing insulin pump market with the Hylenex delivery system.
"Hylenex for insulin pumps offers several advantages to the current standard of care, including faster onset and more physiologic response," said analyst Gregory R. Wade, Ph.D.
"Halozyme has made significant efforts towards commercialization of Hylenex for insulin pumps, we anticipate insight into timing to be the next significant catalyst for this opportunity," added Wade.
He thinks Halozyme may begin to derive revenues from the Hylenex insulin product in the fourth quarter of 2013.
For an analyst ratings summary and ratings history on Halozyme Therapeutics click here. For more ratings news on Halozyme Therapeutics click here.
Shares of Halozyme Therapeutics closed at $6.79 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Canaccord Genuity Downgrades Antofagasta Plc. (ANTO:LN) (ANFGF) to Hold
- WPP Plc (WPP:LN) (WPP) PT Raised to GBP9 at JPMorgan
- Symrise AG (SY1:GR) (SYIEY) PT Lowered to EUR114 at Morgan Stanley
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
